PSEN2 and Alzheimer disease: The five studies based on iPSCs-derived models of AD patients harboring the mutations of PSEN1, PSEN2, and APP point mutation as well as APP duplication, respectively, all report decreasing Aβ peptide levels in iPSCs-derived neurons treated with a γ-secretase inhibitor, an Aβ antibody, and DHA.